March 28, 2014 — VeriTeQ Corp. is rebranding its Q Inside SmartMarker to lead its radiation dosimetry business. Q Inside SmartMarker (previously known as DVS SmartMarker) is the only U.S. Food and Drug Administration (FDA)-cleared implantable radio frequency (RF) radiation sensor that provides localization of a tumor and measures radiation dose at the tumor site. VeriTeQ’s radiation dosimetry products have six FDA clearances and CE approvals, and the company has more than 100 patents, patents pending and exclusive licenses.
Q Inside SmartMarker is an FDA-cleared, implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician’s plan, as even a small deviation from planned dose can have a significant impact on patient survival rates.
Scott R. Silverman, chairman and CEO of VeriTeQ, stated, “Radiation under-dosing and, perhaps more importantly, radiation overdosing have been a top concern of the medical community for years. Confirming the delivered dose of radiation is known to have a direct and significant impact on treatment efficacy and patient survival rates, and our Q Inside SmartMarker can support healthcare providers with this potentially life-saving data.”
According to the ECRI Institute, radiation or computed tomography (CT) overdose make the list of the Top 10 Technology Hazards each year going back at least eight years. These hazards include radiation overdose and other errors during radiation therapy; unnecessary exposures and radiation burns from diagnostic radiology procedures; and exposure hazards from radiation therapy and CT.
Q Inside SmartMarker is compatible with a variety of commercially available systems including, but not limited to, CyberKnife System, Varian kV Trilogy System, TomoTherapy, Siemens MV CBCT and Resonant Medical.
For more information: www.veriteqcorp.com
April 25, 2024 
